<SEC-DOCUMENT>0001055726-25-000013.txt : 20250318
<SEC-HEADER>0001055726-25-000013.hdr.sgml : 20250318
<ACCEPTANCE-DATETIME>20250318160811
ACCESSION NUMBER:		0001055726-25-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250318
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250318
DATE AS OF CHANGE:		20250318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		25748320

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ino-20250318.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:840f00e9-ac83-4320-91ca-fe8d9402f39a,g:010676f8-e129-45bb-9929-f83b9c135f4e,d:c3a32f5cb22746ac8049c331fcfc7ab8-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20250318</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20250318.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-18</xbrli:startDate><xbrli:endDate>2025-03-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic3a32f5cb22746ac8049c331fcfc7ab8_36"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 18, 2025</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Inovio Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-14888</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">660 W. Germantown Pike</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 110</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">PA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">19462</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">267</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">440-4200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.871%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.800%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:2pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 18, 2025, Inovio Pharmaceuticals, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123124x8kex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-123124x8kex991.htm">Press Release, dated March 18, 2025 (filed herewith)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL).</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.935%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 18, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter Kies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ino-123124x8kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iccec74789ded4711945220e24c32d85b_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="picture3a.jpg" src="picture3a.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">Announced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2&#59; data to be included in BLA submission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 were well tolerated and exhibited long-lasting in vivo production </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">DMAb technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13pt">DNA Medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PLYMOUTH MEETING, PA &#8211; March 18, 2025 &#8211; INOVIO (NASDAQ&#58; INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024 and provided a business update and description of operational highlights during the year.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;INOVIO&#8217;s recent progress puts us on the cusp of achieving several long-term goals for our DNA medicines, most importantly the submission of our first BLA and potential transition to a commercial-stage company,&#8221; said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. &#8220;By resolving the previously announced device array component issue, we are back on track to submitting our first BLA for INO-3107 to the FDA. We anticipate starting our submission in mid-2025 with non-device related modules under the agency&#8217;s rolling submission program, assuming it is granted, with the goal of having the complete submission accepted for priority review before the end of the year. We continue to believe that INO-3107 has the potential to be the preferred product candidate offering durable clinical benefit, tolerability and a patient-centric dosing regimen and are moving forward with urgency.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Michael Sumner, INOVIO&#8217;s Chief Medical Officer, said &#8220;While delivering INO-3107 to patients remains our primary focus, we are extremely pleased with recently announced data from a proof-of-concept trial with our DMAb technology that showed durable in vivo antibody production. DMAbs represent a potential breakthrough as they have the ability to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses. They have the potential to transform treatments for infectious diseases, as well as cancer and metabolic disorders by enabling long-term production of therapeutic antibodies and other proteins. Unlike other delivery platforms, our DNA-based approach has demonstrated sustained antibody production without generating anti-drug antibodies, making it a potentially promising long-term solution for conditions requiring continuous therapeutic protein delivery. We look forward to continuing to advance this technology and other promising pipeline candidates through collaborations and other potential strategic opportunities.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Operational Highlights</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-3107 &#8211; Recurrent Respiratory Papillomatosis (RRP)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Made significant progress toward submitting the BLA by completing the drafting of all non-device modules and resolving the previously announced manufacturing issue involving the single-use array component of the CELLECTRA device and enabling the final step of FDA-required device verification (DV) testing.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Reported data from a retrospective trial (RRP-002) showing that patients continued to improve into years two and three following their initial dosing regimen when compared to their response at Week 52.  In the trial, one-half of RRP patients treated with INO-3107 achieved a complete response (CR) and required no surgery in the second 12-month period when evaluated at the end of year two. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Published and presented the full safety and efficacy data for the Phase 1&#47;2 trial, as well as new immunology data demonstrating the ability of INO-3107 to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive recruitment of those T cells into airway tissues and papilloma of RRP patients, which could potentially slow or eliminate papilloma regrowth. This data was published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Nature Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in February 2025.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The European Medicines Agency's Committee for Advanced Therapies (CAT) certified the quality and non-clinical data for INO-3107, confirming that CMC data and nonclinical results available to date comply with the scientific and technical standards to be used in evaluating a potential European Marketing Authorization Application.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">INO-3107 was designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Progressed commercial readiness plans, including refining go-to-market strategy focused on patient and physician needs&#59; driving key strategic decisions on pricing and access, product distribution, targeting and segmentation, and product positioning&#59; and developing plans for the build out of the commercial organization. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Next Steps&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Complete FDA-required design-verification testing - anticipated to be complete in first half of 2025.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Update IND and initiate confirmatory trial.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Submit BLA to the FDA &#8211; anticipate beginning rolling submission process mid-2025 and requesting priority review with goal of completing submission in second half of 2025 and receiving FDA acceptance of submission by year end.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Submit a long-term study protocol to the FDA following BLA submission.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Present and publish clinical, immunology and durability data at targeted scientific and medical conferences in 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-3112 - Oropharyngeal Squamous Cell Carcinoma (OPSCC)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced development plans for a Phase 3 trial for INO-3112 in combination with LOQTORZI&#174; (toripalimab-tpzi), a recently approved PD-1 inhibitor in the U.S. and Europe.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Gained alignment with FDA on the planned Phase 3 trial design and received initial feedback from European regulatory authorities on proposed trial design. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Entered into a clinical collaboration and supply agreement with Coherus BioSciences, Inc. for the use of LOQTORZI in the trial. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Next Steps&#58;  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Finalize protocol of the Phase 3 trial in consultation with the FDA. INOVIO anticipates it will conduct the trial in North America and Europe in patients with locoregionally advanced, high-risk, HPV16&#47;18-positive OPSCC.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Complete ongoing manufacture of drug supply for trial.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Pipeline Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Top-line interim results were announced from an ongoing Phase 1 proof-of-concept trial evaluating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DMAbs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> targeting COVID-19. In the trial, 100% (24&#47;24) of participants who reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies, a common challenge observed in other gene-based delivery </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">platforms, such as adeno-associated virus mediated antibody expression. Additionally, the DMAbs were well tolerated in the trial, with the most common side effects being mild, temporary injection site reactions, such as pain and redness. The trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and the University of Pennsylvania and funded by the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). INOVIO and its partners anticipate additional data to be presented at upcoming scientific conferences and published in a peer-reviewed journal.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Advanced development plans for a Phase 2 trial for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-4201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a potential booster to ERVEBO&#174; (rVSV-ZEBOV), including gaining alignment with FDA on the trial&#8217;s protocol and path to potential approval. In 2025, the company anticipates finalizing the trial protocols and seeking funding to support trial activities. INOVIO also plans to submit the data from its completed Phase 1b trial to a peer-reviewed publication for publication, including FANG assay data indicating that boosting with INO-4201 can elicit neutralizing antibody response comparable to that achieved by ERVEBO, an approved primary series vaccination against Ebola.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Continued efforts to move </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-5401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> into its next stage of development for glioblastoma (GBM), which the company believes will be a controlled Phase 2 trial. INOVIO plans on completing manufacture of drug supply for the next trial during 2025.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Basser Center at the University of Pennsylvania continues evaluating the tolerability and immunogenicity of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-5401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in a fully enrolled Phase 1 study exploring the potential to prevent cancer in people with BRCA1 or BRCA2 mutations.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">INOVIO&#8217;s collaborator, ApolloBio, continues recruitment into its Phase 3 trial evaluating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INO-3100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a potential treatment for HPV 16&#47;18 positive cervical dysplasia in China. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operational and Financial Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Announced appointment of Steven Egge as Chief Commercial Officer in July 2024. Mr. Egge has broad commercial and therapeutic area experience, including in HPV-related diseases and cancers, vaccines and rare diseases, and has overseen or contributed to more than a dozen commercial product launches throughout his career. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Raised over $72 million in gross proceeds from ATM and two offerings of equity securities in April and December 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Cash, Cash Equivalents and Short-term Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; As of December 31, 2024, cash, cash equivalents and short-term investments were $94.1 million compared to $145.3 million as of December 31, 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Total revenues were $117,000 and $218,000 for the quarter and year ended December 31, 2024, respectively, compared to $103,000 and $832,000 for the same periods in 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Research and Development (R&#38;D) Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">R&#38;D expenses for the quarter and year ended December 31, 2024 were $12.9 million and $75.6 million, respectively, compared to $17.3 million and $86.7 million for the same periods in 2023. The decrease in R&#38;D expenses was primarily the result of lower employee and consultant compensation, including stock-based compensation, lower drug manufacturing and clinical trial expenses related to INO-4800, partially offset by an increase in drug manufacturing costs related to INO-3107 and higher engineering professional and outside services related to device development, among other variances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">General and Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> G&#38;A expenses were $7.6 million and $37.0 million, respectively, for the quarter and year ended December 31, 2024, versus $10.2 million and $47.6 million, respectively, for the same periods in 2023. The decrease in G&#38;A expenses was primarily related to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decrease in employee compensation, including stock-based compensation, and a decrease in legal expenses, among other variances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Total Operating Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses were $20.5 million and $112.6 million for the quarter and year ended December 31, 2024, respectively, compared to $27.5 million and $144.8 million for the same period in 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> INOVIO&#8217;s net loss for the quarter and year ended December 31, 2024 was $19.4 million, or $0.65 per basic and diluted share, and $107.3 million, or $3.95 per basic and diluted share, respectively, compared to net loss of $25.0 million, or $1.10 per basic and diluted share, and $135.1 million, or $6.09 per basic and diluted share, for the quarter and year ended December 31, 2023, respectively. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Shares Outstanding&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As of December 31, 2024, INOVIO had 36.1 million common shares outstanding and 50.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding common stock warrants, pre-funded warrants, stock options, restricted stock units and convertible preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO&#8217;s balance sheet and statement of operations are provided below. Additional information is included in INOVIO&#8217;s annual report on Form 10-K for the year ended December 31, 2024, which can be accessed at&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;ir.inovio.com&#47;financials&#47;default.aspx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Cash Guidance</font></div><div style="text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO estimates its current cash, cash equivalents and short-term investments balances to support the company&#8217;s operations into the first quarter of 2026. This projection includes an operational net cash burn estimate of approximately $27 million for the first quarter of 2025. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call &#47; Webcast Information</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO's management will host a live conference call and webcast with slides at 4&#58;30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">http&#58;&#47;&#47;ir.inovio.com&#47;events-and-presentations&#47;default.aspx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About INOVIO's DNA Medicines Platform</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO&#8217;s DNA medicines platform has two innovative components&#58; precisely designed DNA plasmids, delivered by INOVIO&#8217;s proprietary investigational medical device, CELLECTRA&#174;. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. INOVIO&#8217;s proprietary CELLECTRA&#174; delivery devices are designed to optimally deliver its DNA medicines to the body&#8217;s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About INOVIO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO&#8217;s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains certain forward-looking statements relating to our business, including the planned initiation and conduct of pre-clinical studies and clinical trials and the availability and timing of data from those studies and trials, the completion of the FDA-required device verification testing,  the planned submission of a BLA in mid-2025 and request for priority review and goal of FDA&#8217;s acceptance of the submission by the end of 2025, the potential commercial launch of INO-3107 if regulatory approval is obtained, the potential benefits of our product candidates and the expected sufficiency of our cash resources into the first quarter of 2026. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contacts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media&#58; Jennie Willson, (267) 429-8567, communications&#64;inovio.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors&#58; Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations&#64;inovio.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">2024</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">2023</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">ASSETS</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Current assets&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">65,813,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">14,310,862&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Short-term investments</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">28,300,232</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">130,982,913</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accounts receivable from affiliated entities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,199,056</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,405,228</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Prepaid expenses and other current assets, including with affiliated entity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,517,465</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">5,414,097</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total current assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">97,830,050</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">153,113,100</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Fixed assets, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">3,659,818</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">4,960,986</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Investments in affiliated entity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,613,844</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,780,287</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Operating lease right-of-use assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">8,113,840</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">9,491,735</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Other assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,979,654</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">605,315</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total assets</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">113,197,206&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">170,951,423&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accounts payable and accrued expenses</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">16,200,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">19,847,744&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accounts payable and accrued expenses due to affiliated entities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,351,163</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,070,519</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accrued clinical trial expenses</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,021,860</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,365,382</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Common stock warrant liability</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">13,255,188</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Operating lease liability</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,497,360</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">2,406,522</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Grant funding liability, including from affiliated entity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8212;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">109,407</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Convertible senior notes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">16,770,654</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">35,325,584</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">42,570,228</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Operating lease liability, net of current portion</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">9,367,827</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">11,032,066</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">44,693,411</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">53,602,294</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Commitments and contingencies</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Preferred stock&#8212;par value $0.001&#59; Authorized shares&#58; 10,000,000, issued and outstanding shares&#58; 9 at December 31, 2024 and 2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8212;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Common stock&#8212;par value $0.001&#59; Authorized shares&#58; 600,000,000 at December 31, 2024 and 2023, issued and outstanding&#58; 36,099,991 at December 31, 2024 and 22,793,075 at December 31, 2023 </font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">36,099</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">22,792</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Additional paid-in capital</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,799,362,625</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">1,740,954,074</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accumulated deficit</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">(1,730,219,262)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">(1,622,965,136)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Accumulated other comprehensive loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">(675,667)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">(662,601)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">68,503,795</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">117,349,129</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">113,197,206&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">170,951,423&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:67.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">For the Year ended December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">2024</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">2023</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Revenue from collaborative arrangements and other contracts, including affiliated entity</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">217,756&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">832,010&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Research and development</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">75,620,340</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">86,676,563</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">36,996,338</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">47,582,104</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Impairment of goodwill</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8212;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10,513,371</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">112,616,678</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">144,772,038</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Loss from operations</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(112,398,922)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(143,940,028)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Other income (expense)&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Interest income</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4,766,993</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8,133,290</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Interest expense</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(177,833)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1,222,789)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Change in fair value of common stock warrant liability</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2,808,608</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8212;</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(Loss) gain on investment in affiliated entity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1,166,443)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">773,145</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Net unrealized gain on available-for-sale equity securities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2,077,182</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">5,850,626</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other expense, net</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(3,163,711)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(4,711,596)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Net loss</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(107,254,126)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(135,117,352)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Net loss per share</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Basic and diluted </font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(3.95)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(6.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Weighted average number of common shares outstanding</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Basic and diluted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">27,160,863</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">22,173,662</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20250318.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:840f00e9-ac83-4320-91ca-fe8d9402f39a,g:010676f8-e129-45bb-9929-f83b9c135f4e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://inovio.com/20250318" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inovio.com/20250318">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250318_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250318_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20250318_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:840f00e9-ac83-4320-91ca-fe8d9402f39a,g:010676f8-e129-45bb-9929-f83b9c135f4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_18e105e6-2d82-427c-b449-81bf1a244fad_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e7f54ed3-dfa4-4aa2-80e6-228a8c95192d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ff7aaa86-39e7-4dd3-828c-f00ef88190f3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a44b0c50-2410-46c8-b97e-bc64a67d58a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4cabd101-2972-48e1-9c9f-9e0e28234078_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_68ce46f0-da5a-4c5b-a2d7-b7769c5f1ad3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d3d5ae5-5fdd-4470-80ea-329c2ff358de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1880800d-8d7c-4e41-89c9-ad595126297a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_386e261b-7d2e-4c31-9028-ae3ac3b48b4f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6701f467-1c6a-4653-b370-74edee6f2f88_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_be4421f8-0fed-419d-ae8b-9b2df901e764_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1da7a55b-7b82-4617-807f-216c1d724620_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_94f19903-f212-43fa-bd84-53ba4abd4b94_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9c22dbc7-95c5-4238-9627-e928458601ae_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bc8d33e4-35ef-4763-991b-02a9568eaba3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_38033daa-bc9a-4801-b1e6-f440d1341507_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d6abd629-bdd8-4b9a-b653-6dc7c4e91b7b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_933f998c-fb58-4eed-9578-c2fdcc4f7b8f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_adc53fa9-8832-4f96-9f03-6cb6c950b4b0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_62a3d1d5-5a22-45b0-be7e-768ca98dea95_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_223458b3-d7f1-4a8e-9417-5b8f11254245_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a126c831-ce4d-40cb-871b-72da8099dbdc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c4c7d162-0606-427d-be51-30510b8f9d6b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20250318_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:840f00e9-ac83-4320-91ca-fe8d9402f39a,g:010676f8-e129-45bb-9929-f83b9c135f4e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20250318.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a254203a-1f03-45f5-9fbf-fa03e467ebda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_DocumentType_a254203a-1f03-45f5-9fbf-fa03e467ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_204879ed-0cbf-459b-ba30-0a4353887308" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_DocumentPeriodEndDate_204879ed-0cbf-459b-ba30-0a4353887308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c98cbb7d-87bd-4381-9257-4262d5fa0a1b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityRegistrantName_c98cbb7d-87bd-4381-9257-4262d5fa0a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b37913c1-5743-468f-9bc2-426da288d18e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b37913c1-5743-468f-9bc2-426da288d18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1d6735ff-32ea-4fd3-b08d-7f9cd6fb49d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityFileNumber_1d6735ff-32ea-4fd3-b08d-7f9cd6fb49d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9a4092bb-dfd8-4ea5-9f8f-be6a963f1e08" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityTaxIdentificationNumber_9a4092bb-dfd8-4ea5-9f8f-be6a963f1e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_dbe7c102-8cb8-46de-8477-15ca36c8ad69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityAddressAddressLine1_dbe7c102-8cb8-46de-8477-15ca36c8ad69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_62d10971-097b-43f4-864f-7eaec7436852" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityAddressAddressLine2_62d10971-097b-43f4-864f-7eaec7436852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_48fae56e-6406-45d9-b29b-08f35b693eb1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityAddressCityOrTown_48fae56e-6406-45d9-b29b-08f35b693eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6fd467cb-116a-4dac-b86b-101576220e5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityAddressStateOrProvince_6fd467cb-116a-4dac-b86b-101576220e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a1585242-b853-4fdb-885b-36dbdd8db96b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityAddressPostalZipCode_a1585242-b853-4fdb-885b-36dbdd8db96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3691f6fe-eb02-4175-9f88-0fb8caab4f9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_CityAreaCode_3691f6fe-eb02-4175-9f88-0fb8caab4f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ec3e8256-353b-4ca4-abac-b50aa45eaed4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_LocalPhoneNumber_ec3e8256-353b-4ca4-abac-b50aa45eaed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9195c3fc-28f5-4f9a-94d4-1ae41e199335" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_WrittenCommunications_9195c3fc-28f5-4f9a-94d4-1ae41e199335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3f28c3e8-3128-416e-8a96-10e0f793f82f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_SolicitingMaterial_3f28c3e8-3128-416e-8a96-10e0f793f82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f1a61c27-b31f-4a07-b857-6e4aeb97fb68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_PreCommencementTenderOffer_f1a61c27-b31f-4a07-b857-6e4aeb97fb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_29ef28d1-fc93-4898-88a5-3753d280cf6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_29ef28d1-fc93-4898-88a5-3753d280cf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a662bca1-cea5-43c6-ae00-ca754e971620" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_Security12bTitle_a662bca1-cea5-43c6-ae00-ca754e971620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ad7b79f9-64e0-48eb-99d9-d61b1114ae0a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_TradingSymbol_ad7b79f9-64e0-48eb-99d9-d61b1114ae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5014a7b6-7749-41be-b556-bf811c76d721" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_SecurityExchangeName_5014a7b6-7749-41be-b556-bf811c76d721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0487f0c6-e2a7-4cad-9749-6c26a024917c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityEmergingGrowthCompany_0487f0c6-e2a7-4cad-9749-6c26a024917c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8fe5df66-f11a-4264-96d4-585f6094ceff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_EntityCentralIndexKey_8fe5df66-f11a-4264-96d4-585f6094ceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_519b271f-764f-4f60-bc93-88b9baf4a6e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f512931-22fb-45d5-abcc-4cfc1f453d43" xlink:to="loc_dei_AmendmentFlag_519b271f-764f-4f60-bc93-88b9baf4a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>picture3a.jpg
<TEXT>
begin 644 picture3a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ K8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBDH 6BDI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFO(
ML:,[L$11DLQP /6@!U%9B^*-&D9575K%F8X %RA)_6M.@ HHHH **I7FMZ=I
MTHBN[^UM92-P2:94./7!--M=>TR^G$-MJ-I<3,"1'%.K,0.IP#0!?HI*6@ H
MHHH **** "BBB@ HHHH ***@O+ZWT^'SKJXBMHLX\R9PBY/09- $]%4;37=-
MU"80VNH6MS+C/EPSJ[8'4X!J]0 4444 %%)1F@!:*3-&X>M "TU^U!85R'Q%
M^(^E_#O25N[]O-GD.(;6(@R2GV]!ZDUG4J1IP<YNR1$YQA%RD[(ZUFV]\4#G
MFOG?PK\6O'OQ/UZ>U\/IIFF00H&E^U(9"BDD!NH)/'05K^+_ !K\1/A?9QZG
MK+Z-K>GR,(2+='@*2'IUR2.#7FQS"E4I^V2?+WL<D<7"4/:).W<]RXI5KS3X
M;?&?1?'[?9$9['4MNXVLY&2.F4/1O7'7FO2(N,UW4:U.O'GINYT4ZL:L>:+)
M:*3(HW#UKH-A:*3(]:6@ HHJM?:G9Z:J->7<%HKG"F>14!/H,F@"S15&SUS3
M=0F\JUU"UN9<;O+AF5VP.IP#5Z@ HHHH **** "BBB@ HHHH **** "BBH;J
M\@L83-<SQV\0X,DKA5'XF@":BLV'Q)I%Q*D46JV4DDAVHB7"$L?0#/)K2H *
M*ANKR"QA,US/';PKUDE<*H_$U4@\1:3=3)%#J=G+*YPL<=PC,Q]  >: -&BB
MB@ HHHH ***2@!:*3-0WE[;Z?"9KJ>.VA'!DE<(N3[F@">BO+/$W[2OPX\+?
M:%NO%%K<3P/LDM[+,\@.<=%%<+KG[<7@33TC_LVTU;6&;[P6#R-OXN1F@#Z-
MHKY:_P"&]_#8_P"95UC_ +^P_P#Q56=-_;M\(W-Y%'>:'K%A Q^:<^7)M_X"
MIR: /IRBO&-$_:W^&.N7+PG7FTW"[O,U&V>!#]&(KTW0?%6C^*K6.YTC5+34
MX73>IMIE?*^N <X^M &U124M !1110 4444 %%%% !1110 4444 %%%% !11
M10 5@^/>? OB('_H&W/_ **:MZL+QY_R(WB+_L'7'_HIJ /RN\%V\7_"2>'_
M -VG_'[;?PC_ )Z+7ZUQ_P"K7Z"OR8\%_P#(R>'_ /K]MO\ T8M?K/'_ *M?
MH* 'T444 ?!7[=44<GQBTXNBM_Q)H>6 _P">LU>"^']6OO"NM6FKZ1.]AJ5K
M()8;B+Y2#[GN".".G->^?MT?\E@T[K_R!H>AQ_RUFKSC0/@WJGBKX4ZAXRTA
M6OGTV\:&[LHT^80A0WFH.^.XZXY[4 ?=WP/^,VF?&+PO%>VK+;ZK;A8]1L&X
M:&3'4#NC=5/]:]+R/6ORS^%?Q.U3X3^+K77=)VS!1Y=S;-PEQ"3RI]#W!'?%
M?I1X"\::;\0O"^GZ_I$IEL;M-PW$;HVZ%&'8@\4 =+129I: "BBB@ HHHH *
M*** "O _VVE5_@7<!@&']H6O!'^W7OE>"?ML?\D+N/\ L(6O_H= 'SC^Q3$B
M?'>V*HJG^S;KD#_<K]":_/G]BO\ Y+M;?]@VZ_\ 9*_0:@ IK4ZD:@!AIDS*
MD)8L$5>2S'@#U-+)D+TSS7SQ\8OB)#K'CBT\(W&H-I^@1RQ_VG-'D>9D@["P
MZ)C&?<G/2N/$XF.&BI3W9S5JT:$5*74ZSQ?^T-HGAN2:.QMKG7'AD,<LUNN(
M$?ICS#P>>,"N)/[4FM*J7$WAB%+%C_KA(^,9[,1M_7K7M=YX-T?4/",VAQ6L
M":;<0>4JP *H!'RLI'X$'VKQ[X,ZDWA3Q'J/P\\1Q),HE:2T\Y,H3C)QN[,,
M$>^17BXF6+C6BO:\L9=EU['G5GB/:1_>63\NIU?A?]H[POKJF*\\[2;CDA+C
M#*PQD?..,GTKROPKIMQ\=OBM>7VHL[:5;GS2FXX6('$<8ST#8R>_-=;^T%\-
M_#6B>&VUJPLEL-0:9%'D-M63<WS$KT) KSKX4_$VY^%]]BZL6ETO4-LK87$F
M!QO0_P 0]J\K$XBK[>&'Q;]U:Z=?4XZU6?MHT<0[I=OU/1OA-);Z'\=O%^D1
MPB.*8,L048"!"#CZ?-6G^U7J"P>#M.LV_P!9<7.\8_V%.?\ T(?G6!X0U'39
M_P!HQ]1T^Z6XL]2LVG1QW9U4D>WW>E:O[3$EM>ZIX.L)G7Y[LF52<8C8JI)]
MNM=G-!8"I"#T3:^]F]X_59Q3TO\ J9'Q:^$K:3IEMXP\.9LYK>*.6YBB^4KA
M1^\3'0CN/QK?\._M*Z3!X/MKC5P\FN*#&]K:Q_ZPCHP)X 8?J".U9?Q6^/%M
M:V,WA[PV4NF:+R);T#=''D;2J#^)L?A7E_PK\.V&I?$*QTG7[24QR[@D,A*#
M>!N&_P!B >/<5P3Q7L,2H8'KH^USEE75&ORX?KOVN>L6/[0WB;Q-?.OA[P=]
MLMNH:21L@9P26 V]?2M3P7\>[[Q!)J(O/#[R0Z><W%SI;F=(UY^;:<%NF>.W
M-6/CCXNA\#^%8/#^BPQP7^IYACBMU \N/HQ '0G.T>Y)[5TOPA\ +X#\(P6T
MHS?W!$UTPY^<@87/HH 'X$]Z]JE]9>(]FJE[;Z*R[)'HP]M[7EY[VW.OT75K
M/6K%+RPN([JWDZ/&<CZ>Q]C6BO>OG?Q#\0-.^&_QA<:9=M-IM[A=7LH5S'',
M>!(O^UTW >GJ:^@[2020AP00PR"#D'WKUL/B8UW**>L79G?2K1J-QOJMR>O&
M?VK/ADOQ)^%=YY-NLVJ:3F_M,C).T?.@]-RY_*O9JBF7>NTKN5@05(R#7<=)
M^4_PW\72_#SQKHWB.S7#64RNX4<O&>'3CKE<\'OCTK]3M$U6VUS2;74+259K
M6ZB6:*13D,K $<_C7YM?M!?#S_A6?Q4U?3(8V33[A_MMF6R1Y<AR5R>NTD@^
MG%?4/[%/Q$/B3P%/X9NI-U[H+@0Y)):V<DI^"G<N/0#UH ^DZ*:N=O/6G4 %
M%%% !1110 4444 %%%% "5\;_MV?$475YI7@>UD5DB'V^^4<_.01$A]" 6;!
M_O*:^M/$6LVWAO2;_5KYC'96-N]Q,PY.U02<#N>,8K\M/''BZ\\>>+M5\0WW
M-QJ%P9=FXD(I.$0$] %P!]* /7_V-/AC#XN^)C:Y<6R/I^@(LZDH"#<L2(OQ
M&&?([H*^_P"/_5K]*\I_9O\ AN?AG\*M+L[B(KJM\/MU[D8(DD PI_W5"@CU
M!/>O5USM&>M 'BW[8BA_@+K@8!AYMOP1_P!-5KXL_9ZAC7XX^"2(U!_M).0!
M_=:OM3]L+_D@VM_]=;?_ -&K7Q=^SW_R7#P3_P!A)/\ T%J /TZHHHH ***3
M- !63K_B#3?"NFW&HZK>P:?8Q M)<7+A5'!/YX'0<USOQ4^*6B_"3PW)K&M3
M'YF*6UG&1YMU)V51_,] *_//XJ?&+Q%\6]6:]UR[VV4;E[73HSB"VSQT[G'&
M3R: /H'XG_MQ.SR67@33@%#;?[5U&,G/3[D6?]X?-]17S3XB\;>*/B)?;=6U
M?4==N9<;8&=G# =,1J,''^[7L?P9_9 U[QU'#JGB8S>'-%8@I R_Z5.I7((!
MX09QRW/7I7V#X$^$OA3X:VJP>'M%@M).K73KOG<CC+.>>] 'P=X5_9=^(_BR
M'S;;PZVG0;5=)-3E6 .K#@J.2>/85Z19_L&>)Y(87N?$VEVSMAI(EAD<H>X#
M=#7V\.@I: /DBW_8#LOLX\_QC=";N([1-GZG-8>H?L#ZRMP1I_BRQ-OV^TVK
M[O\ QTXK[3HH _/7Q-^QO\1O#_VF2TM+/6[>$95K.<+))SU6-N?PS7E-]I/B
M/X=ZLRW-MJ7AO44;8S$/;N3P<!APPZ< D<5^L%96N>'--\2:>]EJMA;ZC:2*
M5:&YC#C!&#UZ<>E 'PS\.?VS/&'A5XK?Q$J^*-.!RTDN$NE!.20XX8]@"!7U
M[\,?C%X7^+&GF?0+]9;F,*T]C-\D\.<]5[C(/(XKPOXM_L2V-_YVH> Y_P"S
M[HG<=)NFS Q).=CGE, C@Y''O7RBR^(?AOXI <7N@:]82 CK'(C*W'L5X]P<
M4 ?J_FEKYX_9[_:AM?BA-#H/B#R=/\4;?W3+\L5Z ,G;_=?&3M[]J^ALB@!:
M*** "BBB@ HHHH **** "BBB@ HHHH *PO'G_(C>(O\ L'7'_HIJW:PO'G_(
MC>(O^P=<?^BFH _++P7_ ,C)X?\ ^OVV_P#1BU^L\?\ JU^@K\F/!?\ R,GA
M_P#Z_;;_ -&+7ZSQ_P"K7Z"@!]%%% 'P9^W1_P EAT[_ + T/_HV:O6OV$@&
M^&>N C(.I,"#_N+7DO[='_)8=._[ T/_ *-FKUO]A'_DFNM_]A-O_0%H \<_
M:H_9_/PTU5_$NBH7\-:A,?,AQS9S-_#_ +C'IZ'CTKF_V<_CE<?![Q6L=Y/(
M_A>^?;>P ;O*/03*.Q'?'45^A.O:#8^)M)N],U6TCO;"ZC,4\$@RKJ?ZCK7Y
MQ?';X-WOP;\826FR6;0[IB^G7L@R)$Z[&;^^O<=QS0!^DFE:A;:O9V]_9W$=
MU:W""2&:%MRNA&00:O9'K7P]^R3^T(WA6\M_!&O29T:ZDVZ?=N<?992?]6W^
MP3T/8_6OMR/[PSU_SQ0!-1110 4444 %%%% !7@G[;'_ "0NX_["%K_Z'7O=
M>"?ML?\ )"[C_L(6O_H= 'SI^Q7_ ,EVMO\ L&W7_LE?H-7Y\_L5_P#)=K;_
M +!MU_[)7Z#4 %-=MHI=P]:@O+B*VMWFFE2**,%WD=@JJHY))["C?03=E=BL
MW4CI7RCX.\(V'Q*\=>-K*[!2XD,TUK*3DQ,)NOZ@?3->@>-/VQ?A?X)N9;>3
M7_[6N8F,<EOI41G8<=<\*1[@FOG+P;^U5X0\)_%74->4:F='O))]ZK9CS/+9
MBR@+NXPVW\JY\;D6.QLJ4HT9.-^Q\MC\RP7/",ZBWUU/>_A'\0+KP'K#>!?%
M@-J\3[+.YE/RX)X7)_A/\)_"M3]H;P7,UI;>,=,/EZCI15I&48)C!R'S_L')
M^A->/_%/]J#X1_$C0S_I&I0:M ,VL[6/.3_"WS?=/Z=16;X9_;;5O!O_  C-
MAX;U+Q9XE=3#:0^3D21[2 7 R3MXSZCG(H609C[-X>K3?+TD^AE_:>$<7A^>
M_9HZKXF?$2;XMQ^%=)TZ'==L%,\(7I<M\H /L,MCW%>[77P@T/5O!6G^'KZV
M\Q;&%4BN$)\Q&QRRM]2:X/\ 9W^!M]X3@3Q-XN$4OBBX4F*R@_U&F1L.47^]
M(>[?@..OO42E>H.?>N"EEW)*3Q#4I/3Y(]?!T95(NK77O2_(^;_^&>?$WA#7
M+?5?#6HVMY-;S;XTN@8SMQ@[CR#WZ"F>)/@W\1/B!K%O<Z_+ID"QH85DA?.Q
M"2<8 R>:^ECGM30IK+^R,/R\JOR]C7ZA1Y>76WX'DOP[_9\TCP;/%?WS?VOJ
MB<JSKB*,^JKZ\=3ZUYK\>=-E\&_%+3?$:(98KAHIUW8 +Q$ H/; 4D^]?4N>
M<8.:YGXA>!+/X@>'I=.NQY4GWX+A5!:)QT8?R_&IQ66P>&=/#KE:U0J^#BZ7
M)25FM5ZGC'PITJZ^+'Q%O?&FJQL;"SD"VD; 8W#E5_X #D^Y!KL/C1\6CX3M
M1H6D,TWB&\ 15AY: -QG']X] .O?Z^<77Q0\0?L_V,?A#4O#\:Q,LIM-?6<)
M;LS$D AAR^2>,YP#Z<^;?#O]I'X;^"_$%[K'B6;5]9\0^:P$T-H)HT/=E8MR
MQ]>PX%5A,OQE>"H8:#E.2NY+H>/+'4L,O8SERR?Q-G6_$'X7OX'^'^EWNH#?
MKFH7F;AF;)C!1CLSZYP2?7Z5](_";6#KOP\T*\9?+9K94*YS]S*9S[[:^7OB
MA\=M#^-=CIUUX=.H1Z?9F42+?0>5F3 P5&3G W?G79?#?]M+X4V^C:;HLE]=
MZ/\ 9;9$:>\M&2$L -VTJ6)R<]N]5EV65XXVM&C!V@DGZ^88;&X2CB)*-1*-
MEOU/I_<#WS3EK'\-^)M)\5:7%J&D:E;ZE92\I/;RAU/&<9!X/J#R*V%KVFG%
MV>A]5&2FN:+NCYS_ &U_AJ/$W@&'Q/:Q@ZAH3;I2!R]LYPX]3M." />OE7X!
M_$5OAC\3])U9Y/+TZ5OLE\&/'DR$ L?3:=K9] 1WK]*]7TVWUC3KJQND$EK=
M1-#*A.-R,"",_0U^6OQ&\$W'P]\<:SX=NQEK.=EC=E($D1Y1AR3@J1^5!1^J
M5NP>/>K;E;D-ZC%2UXW^RK\23\0OA39+=3>;JFDG[#=%CEFV@;)#D\[D*DGI
MG([5[)0 4444 %%%% !1110 4F<=>*6J]U(L*M)(XBB4%G=F "@#DD]OK0!\
MU_MP?$8:'X/M/"-K+B[UIA+<;3RENAR 1_M.!@C^X?6OG/\ 9M^&Y^)?Q6TV
MVEBW:98G[?>97(:-",(<\$,VT$=<%O2L;XW?$*3XG?$S6=;#LUGYGV>R5LC;
M GRIQDX)QDXXR37U]^QQ\.6\'_#+^VKF'9J'B!A=99?F$ !$0/)!R"7'^_[4
M ?0$2[8P.M/IJ_=%.H \6_;"_P"2#:W_ -=;?_T:M?%W[/?_ "7#P3_V$D_]
M!:OM']L+_D@VM_\ 76W_ /1JU\7?L]_\EP\$_P#823_T%J /TZHHHH *YKQY
MXTTWX?>&=0U[5YU@L[1"_)P9&Q\J+ZLQX'Y]JZ3/;O7P9^V/\7'\8>-F\)V,
MQ.C:+)B8*>)KK^(GC^ ?*/?)[T >3?%#XF:U\7/%DVM:L[,Y/EVEG'DI;1Y^
M6-!ZGN>I-?5G[-_[+-KX;L[7Q-XPLUNM;D EM=/E&Z.S'9F'1I#Q[#I7"?L=
M? Z+Q-?'QQKMJLVG6<GEZ;"YRLDP/S2D=PG09_BS_=K[;7.T9ZT "_=%+110
M 4444 %%%% !1110 5YA\;/@AI'QGT#[-=*MEK-N"UEJ:)EHF/\ "W]Y#W';
MJ.17I]% 'Y0^*?"VN?#7Q9/I.J12:9K%A(&5HVQGG*RHW\0.,@CW[C%?>'[,
MOQRB^+7ADV5^WE^)M+11>;N/M"]!,OUX!'8_6I/VF/@HOQ9\&M/8Q!?$FEH\
MUFZJ,S+_ !0$^C8R/0X]Z^%/AWXXU+X7>-M/UZR#1SV<FV>W<,OF1YQ)&PZ]
M,C'J* /U4W#UI:R/#NMV?BC0]/U?3W6:SO85GAD4C[K#.#@]1T/N#6O0 444
M4 %%%% !1110 4444 %%%% !6%X\_P"1&\1?]@ZX_P#135NUA>//^1&\1?\
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MVTDN[/@\[KQKXF&"J-\BU=MWV1K_ !8_8U\6_"!8?$W@+5KW5Q:!2ZVN8[Z
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M&K7Q=^SW_P EP\$_]A)/_06K[1_;"_Y(-K?_ %UM_P#T:M?%W[/?_)</!/\
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M&/[P&/2O>_M"IAZDL*I\L):P:T2[7\N_F?._4(8BC'%.+E.%U-/KW_X!\O\
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MIW_8&A_]&S5ZY^P?_P DUUO_ +";?^@+7D'[=4T:_&'3MTBK_P 2:'[S ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 18,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  6!<EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  6!<EK8.W]?[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MP=VA\C78Z@R*_IU\YO4TN(8'Y>1UNU=^#T.J?-['+7H"LS$J9N1]S-:U/+C
MR=%QC[:Y]B\#V,5 /C(2\Q4(>:TKT-7[7?C^PJBTV/DNE8%]='&ZX0SLP3X
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ !8%R6I>*NQS
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M4$L! A0#%     @ !8%R6D;'34B5    S0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  %@7):V#M_7^X    K @
M$0              @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  %@7):F5R<(Q &  "<)P  $P              @ '@ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    (  6!<EK:I?_Y7P0  !<1   8
M      " @2$(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  %@7):GZ ;\+$"  #B#   #0              @ &V#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    (  6!<EJ7BKL<P    !,"   +              "
M 9(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  6!<EJJQ"(6,P$  "("   /
M              "  7L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  %
M@7):)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  %@7):99!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ino-20250318.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ino-20250318.htm">ino-20250318.htm</File>
    <File>ino-20250318.xsd</File>
    <File>ino-20250318_lab.xml</File>
    <File>ino-20250318_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20250318.htm": {
   "nsprefix": "ino",
   "nsuri": "http://inovio.com/20250318",
   "dts": {
    "inline": {
     "local": [
      "ino-20250318.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20250318.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20250318_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20250318_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://inovio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250318.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250318.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001055726-25-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-25-000013-xbrl.zip
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MX0_?=09O])Z(*.!*$.6@1^,M2 <EZGWCT[H68=@NH4IE.;62MGTEK:0Z4-$
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M^9?6QH9E^F2-DEM#R4)07)*'!DT"DYH 9Q6K"S*/B_ #RB)0C J5^_?F/YJ
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ME1*:)EC!IF]'SGNA:X<*CA&ERN!,45RKE94B=5M2(K9M4&:4T)%Y)7EOEID
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M,@GRB)M!C2H2 4T^(5EQJ9+/C$9FI6J<77(S?0]+D<KL8&J>CWIHJ"[C"#,
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M90B_"O&99L-J-D_$%">#7P@6J;1.RK HT^UUG&ZW]S5T6(O -:"B6N%Z6Z'
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M8_]6MM1[E;!L*MB_!$^8B$,1+L7'[VYBWL6,?R!K_3'ABSD(M_>-;"OS\64
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M87@:9V,G9S9Z7C+90)N5K4"6/V>;25>V3TI;6KH5U:66KZ^R'Q/KR5+&I#P
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M,3(S,3(T>#AK97@Y.3$N:'1M4$L! A0#%     @ !8%R6@(ADL7=#P  0Y
M !               ( !Q2H  &EN;RTR,#(U,#,Q."YH=&U02P$"% ,4
M"  %@7):@>\3AET"  #D!@  $               @ '0.@  :6YO+3(P,C4P
M,S$X+GAS9%!+ 0(4 Q0    (  6!<EI-C2>^5@H   98   4
M  "  5L]  !I;F\M,C R-3 S,3A?;&%B+GAM;%!+ 0(4 Q0    (  6!<EII
M3Q=MTP8  .LR   4              "  >-'  !I;F\M,C R-3 S,3A?<')E
:+GAM;%!+!08     !0 % $0!  #H3@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ino-20250318_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20250318.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2025-03-18</startDate>
            <endDate>2025-03-18</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001055726</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-03-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
